Leerink Swann Initiates Paratek Pharmaceuticals With Outperform

Leerink Swann initiated coverage on Paratek Pharmaceuticals Inc PRTK with a Outperform rating. The target price for Paratek Pharmaceuticals is set to $43. Paratek Pharmaceuticals shares have dropped 25.03 percent over the past 52 weeks, while the S&P 500 index has surged 12.95 percent in the same period. Paratek Pharmaceuticals' shares closed at $27.80 yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: InitiationAnalyst RatingsLeerink Swann
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!